Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2021

Three months ended April 30, 2021	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	25,018		$	7,779			—			—		$	32,797

Operating costs and expenses:
Cost of revenues		12,733			4,018			—			—			16,751
Research and development		173			643		$	20			—			836
Selling, general and administrative		7,029			2,810			17		$	2,226			12,082
Legal and related expenses		95			10			—			956			1,061
Total operating costs and expenses		20,030			7,481			37			3,182			30,730

Operating income (loss)		4,988			298			(37	)		(3,182	)		2,067

Other income (expense):
Interest		(4	)		11			—			53			60
Other		1			2			—			(91	)		(88	)
Foreign exchange gain		—			(33	)		—			—			(33	)
Net income (loss)	$	4,985		$	278		$	(37	)	$	(3,220	)	$	2,006

Depreciation and amortization included above	$	399		$	208		$	—		$	66		$	673

Share-based compensation included in above:
Selling, general and administrative		9			41			—			208			258
Cost of revenues		39			—			—			—			39
Total	$	48		$	41		$	—		$	208		$	297

Capital expenditures	$	1,544		$	180		$	—		$	23		$	1,747

Three months ended April 30, 2020	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	9,739		$	6,417			—			—		$	16,156
Grant income		747			—			—			—			747
Total		10,486			6,417			—			—			16,903

Operating costs and expenses:
Cost of revenues		9,133			3,345			—			—			12,478
Research and development		395			580			188			—			1,163
Selling, general and administrative		5,902			2,667			—			2,492			11,061
Legal fee expense		52			—			—			1,873			1,925
Total operating costs and expenses		15,482			6,592			188			4,365			26,627

Operating loss		(4,996	)		(175	)		(188	)		(4,365	)		(9,724	)

Other income (expense):
Interest		(7	)		11			—			83			87
Other		1			4			—			130			135
Foreign exchange loss		—			(358	)		—			—			(358	)
Net loss	$	(5,002	)		(518	)		(188	)		(4,152	)		(9,860	)

Depreciation and amortization included above	$	373			278			—			66			717

Share-based compensation included in above:
Selling, general and administrative		21			14			—			172			207
Total	$	21			14			—			172			207

Capital expenditures	$	225			60			—			—			285

Nine months ended April 30, 2021	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	70,229		$	22,689		—			—		$	92,918

Operating costs and expenses:
Cost of revenues		37,436			11,718		—			—			49,154
Research and development		454			1,868	$	66			—			2,388
Selling, general and administrative		19,552			7,848		50		$	5,659			33,109
Legal and related expenses		191			16		—			3,786			3,993
Total operating costs and expenses		57,633			21,450		116			9,445			88,644

Operating income (loss)		12,596			1,239		(116	)		(9,445	)		4,274

Other income (expense):
Interest		(14	)		29		—			(55	)		(40	)
Other		30			6		—			(91	)		(55	)
Foreign exchange gain					428		—			—			428
Net income (loss)	$	12,612		$	1,702	$	(116	)	$	(9,591	)	$	4,607

Depreciation and amortization included above	$	1,189		$	581	$	—		$	198		$	1,968

Share-based compensation included in above:
Selling, general and administrative		28			73		—			473			574
Cost of revenues		66			—		—			—			66
Total	$	94		$	73	$	—		$	473		$	640

Capital expenditures	$	2,425		$	378	$	—		$	67		$	2,870

Nine months ended April 30, 2020	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	35,032		$	20,715			—			—		$	55,747
Grant income		747			—			—			—			747
Total		35,779			20,715									56,494

Operating costs and expenses:
Cost of revenues		30,351			10,223			—			—			40,574
Research and development		1,118			1,599		$	565			—			3,282
Selling, general and administrative		18,012			7,954			—		$	6,927			32,893
Legal and related expenses		140			1			—			5,540			5,681
Total operating costs and expenses		49,621			19,777			565			12,467			82,430

Operating income (loss)		(13,842	)		938			(565	)		(12,467	)		(25,936	)

Other income (expense):
Interest		(29	)		45			—			479			495
Other		20			(1	)		—			315			334
Foreign exchange loss		—			(88	)		—			—			(88	)
Net income (loss)	$	(13,851	)	$	894		$	(565	)	$	(11,673	)	$	(25,195	)

Depreciation and amortization included above	$	1,174		$	781		$	—		$	196		$	2,151

Share-based compensation included in above:
Selling, general and administrative.		88			58			—			582			728
Total	$	88		$	58		$	—		$	582		$	728

Capital expenditures	$	514		$	205		$	—		$	—		$	719